MiNK Therapeutics (INKT) Competitors $15.09 -0.26 (-1.69%) Closing price 04:00 PM EasternExtended Trading$15.28 +0.19 (+1.23%) As of 04:43 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock INKT vs. RNAC, TNXP, JBIO, ALLO, AVIR, LYEL, FENC, ACIU, EDIT, and IMMPShould you be buying MiNK Therapeutics stock or one of its competitors? The main competitors of MiNK Therapeutics include Cartesian Therapeutics (RNAC), Tonix Pharmaceuticals (TNXP), Jade Biosciences (JBIO), Allogene Therapeutics (ALLO), Atea Pharmaceuticals (AVIR), Lyell Immunopharma (LYEL), Adherex Technologies (FENC), AC Immune (ACIU), Editas Medicine (EDIT), and Prima BioMed (IMMP). These companies are all part of the "pharmaceutical products" industry. MiNK Therapeutics vs. Its Competitors Cartesian Therapeutics Tonix Pharmaceuticals Jade Biosciences Allogene Therapeutics Atea Pharmaceuticals Lyell Immunopharma Adherex Technologies AC Immune Editas Medicine Prima BioMed Cartesian Therapeutics (NASDAQ:RNAC) and MiNK Therapeutics (NASDAQ:INKT) are both small-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their earnings, analyst recommendations, valuation, profitability, dividends, risk, media sentiment and institutional ownership. Which has stronger earnings and valuation, RNAC or INKT? MiNK Therapeutics has lower revenue, but higher earnings than Cartesian Therapeutics. MiNK Therapeutics is trading at a lower price-to-earnings ratio than Cartesian Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioCartesian Therapeutics$1.03M239.24-$77.42M-$52.83-0.18MiNK TherapeuticsN/AN/A-$9.51M-$2.88-5.24 Do analysts prefer RNAC or INKT? Cartesian Therapeutics presently has a consensus price target of $40.00, indicating a potential upside of 323.73%. MiNK Therapeutics has a consensus price target of $37.50, indicating a potential upside of 148.51%. Given Cartesian Therapeutics' stronger consensus rating and higher possible upside, equities analysts clearly believe Cartesian Therapeutics is more favorable than MiNK Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Cartesian Therapeutics 0 Sell rating(s) 1 Hold rating(s) 4 Buy rating(s) 0 Strong Buy rating(s) 2.80MiNK Therapeutics 1 Sell rating(s) 1 Hold rating(s) 2 Buy rating(s) 1 Strong Buy rating(s) 2.60 Is RNAC or INKT more profitable? Company Net Margins Return on Equity Return on Assets Cartesian TherapeuticsN/A N/A -6.36% MiNK Therapeutics N/A N/A -227.24% Does the media prefer RNAC or INKT? In the previous week, MiNK Therapeutics had 5 more articles in the media than Cartesian Therapeutics. MarketBeat recorded 6 mentions for MiNK Therapeutics and 1 mentions for Cartesian Therapeutics. MiNK Therapeutics' average media sentiment score of 1.02 beat Cartesian Therapeutics' score of 0.00 indicating that MiNK Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Cartesian Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral MiNK Therapeutics 4 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Which has more volatility & risk, RNAC or INKT? Cartesian Therapeutics has a beta of 0.39, meaning that its share price is 61% less volatile than the S&P 500. Comparatively, MiNK Therapeutics has a beta of 0.33, meaning that its share price is 67% less volatile than the S&P 500. Do insiders & institutionals have more ownership in RNAC or INKT? 86.9% of Cartesian Therapeutics shares are held by institutional investors. Comparatively, 2.9% of MiNK Therapeutics shares are held by institutional investors. 60.3% of Cartesian Therapeutics shares are held by insiders. Comparatively, 22.5% of MiNK Therapeutics shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term. SummaryCartesian Therapeutics beats MiNK Therapeutics on 9 of the 14 factors compared between the two stocks. Get MiNK Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for INKT and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding INKT and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart INKT vs. The Competition Export to ExcelMetricMiNK TherapeuticsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$68.21M$3.13B$5.76B$10.41BDividend YieldN/A2.37%5.74%4.63%P/E Ratio-5.2420.5976.5226.72Price / SalesN/A385.20496.69161.98Price / CashN/A45.3237.1760.63Price / Book-3.059.6513.716.39Net Income-$9.51M-$53.02M$3.29B$271.62M7 Day Performance4.79%1.03%0.92%2.76%1 Month Performance2.65%7.85%6.19%9.54%1 Year Performance96.74%10.32%81.04%31.52% MiNK Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)INKTMiNK Therapeutics3.6916 of 5 stars$15.09-1.7%$37.50+148.5%+107.4%$68.21MN/A-5.2430News CoveragePositive NewsShort Interest ↓Gap UpRNACCartesian Therapeutics1.6688 of 5 stars$9.81-1.5%$40.00+307.7%-34.0%$256.10M$38.91M-0.1964News CoveragePositive NewsTNXPTonix Pharmaceuticals3.198 of 5 stars$28.80-7.7%$70.00+143.1%+95.5%$252.78M$9.83M-0.7350News CoverageJBIOJade Biosciences2.2041 of 5 stars$7.69-0.9%$16.00+108.1%N/A$250.90MN/A-0.2520Positive NewsALLOAllogene Therapeutics2.916 of 5 stars$1.14-3.0%$8.44+644.0%-58.0%$249.62M$20K-1.01310AVIRAtea Pharmaceuticals2.1625 of 5 stars$3.16-4.4%$6.00+90.2%-25.6%$249.59MN/A-1.9570News CoveragePositive NewsShort Interest ↑LYELLyell Immunopharma2.2784 of 5 stars$12.80-3.8%$15.00+17.2%-53.2%$247.14M$60K-0.53270FENCAdherex Technologies2.2738 of 5 stars$8.79-2.7%$13.33+51.7%+71.1%$245.50M$47.54M-20.9410News CoverageACIUAC Immune2.652 of 5 stars$2.42+1.5%$10.00+314.1%-30.6%$243.49M$31.02M-4.18140Positive NewsEDITEditas Medicine3.9787 of 5 stars$2.70-0.6%$5.10+89.2%-22.7%$241.44M$32.31M-0.94230IMMPPrima BioMed1.0214 of 5 stars$1.64-1.5%$7.00+328.1%-24.2%$240.00M$6.69M0.002,021Gap Up Related Companies and Tools Related Companies Cartesian Therapeutics Competitors Tonix Pharmaceuticals Competitors Jade Biosciences Competitors Allogene Therapeutics Competitors Atea Pharmaceuticals Competitors Lyell Immunopharma Competitors Adherex Technologies Competitors AC Immune Competitors Editas Medicine Competitors Prima BioMed Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:INKT) was last updated on 9/19/2025 by MarketBeat.com Staff From Our PartnersTrump’s national nightmare is herePorter Stansberry and Jeff Brown say a new U.S. national emergency is already underway — and it could trigger ...Porter & Company | SponsoredHe Called Nvidia at $1.10. Now, He Says THIS Stock Will…The original Magnificent Seven returned 16,894%—turning $7K into $1.18 million. Now, the man who called Nvi...The Oxford Club | SponsoredOut of 18,347 Cryptocurrencies... This is the ONLY OneThe Single Most Undervalued DeFi Protocol You've Never Heard Of If there's one cryptocurrency you should b...Crypto 101 Media | SponsoredStunning new initiative unfolding in the White House?what I just learned about what’s unfolding in the White House is truly stunning… And you need to see it for...Paradigm Press | SponsoredA New Way to Double Your Retirement Income?Bloomberg reports that a new class of investments is “entering a golden era,” with yields fueling a retail boo...Investors Alley | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredStrange crypto pattern discovered by 40-person research teamSomething unusual is happening inside a 40-person crypto research firm. They're helping 8,000+ ordinary peo...Crypto Swap Profits | SponsoredIRS Wants Another Check on Sept 15th—What If You Could Keep It Instead?On September 15th, the IRS collects another round of quarterly tax payments—targeting self-employed profession...American Alternative | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding MiNK Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share MiNK Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
